NIOX Group PLC (NIOX) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.130x

Based on the latest financial reports, NIOX Group PLC (NIOX) has a cash flow conversion efficiency ratio of 0.130x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX8.80 Million ≈ $1.07K USD) by net assets (GBX67.60 Million ≈ $8.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NIOX Group PLC defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

NIOX Group PLC - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how NIOX Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.

NIOX Group PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NIOX Group PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Timah Resources Ltd
AU:TML
0.007x
Arkadia Digital Media Tbk PT
JK:DIGI
0.084x
Colabor Group Inc.
TO:GCL
0.101x
Universal Biosensors Inc
AU:UBI
-0.301x
Cullen Resources Ltd
AU:CUL
0.183x
Eguana Technologies Inc
V:EGT
0.006x
Railway Metrics & Dynamics Sweden AB
ST:RMDX
0.026x
Damon Inc. Common Stock
NASDAQ:DMN
0.392x

Annual Cash Flow Conversion Efficiency for NIOX Group PLC (2013–2025)

The table below shows the annual cash flow conversion efficiency of NIOX Group PLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see NIOX Group PLC market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 GBX67.60 Million
≈ $8.22K
GBX15.80 Million
≈ $1.92K
0.234x -19.15%
2024-12-31 GBX59.50 Million
≈ $7.24K
GBX17.20 Million
≈ $2.09K
0.289x +108.83%
2023-12-31 GBX83.80 Million
≈ $10.20K
GBX11.60 Million
≈ $1.41K
0.138x 0.00%
2023-12-30 GBX83.80 Million
≈ $10.20K
GBX11.60 Million
≈ $1.41K
0.138x +69.21%
2022-12-31 GBX81.90 Million
≈ $9.96K
GBX6.70 Million
≈ $815.20
0.082x 0.00%
2022-12-30 GBX81.90 Million
≈ $9.96K
GBX6.70 Million
≈ $815.20
0.082x +290.34%
2021-12-31 GBX66.80 Million
≈ $8.13K
GBX1.40 Million
≈ $170.34
0.021x 0.00%
2021-12-30 GBX66.80 Million
≈ $8.13K
GBX1.40 Million
≈ $170.34
0.021x +105.80%
2020-12-31 GBX66.10 Million
≈ $8.04K
GBX-23.90 Million
≈ $-2.91K
-0.362x 0.00%
2020-12-30 GBX66.10 Million
≈ $8.04K
GBX-23.90 Million
≈ $-2.91K
-0.362x -22.16%
2019-12-31 GBX84.80 Million
≈ $10.32K
GBX-25.10 Million
≈ $-3.05K
-0.296x 0.00%
2019-12-30 GBX84.80 Million
≈ $10.32K
GBX-25.10 Million
≈ $-3.05K
-0.296x -33.41%
2018-12-31 GBX183.00 Million
≈ $22.27K
GBX-40.60 Million
≈ $-4.94K
-0.222x 0.00%
2018-12-30 GBX183.00 Million
≈ $22.27K
GBX-40.60 Million
≈ $-4.94K
-0.222x -43.13%
2017-12-31 GBX371.60 Million
≈ $45.21K
GBX-57.60 Million
≈ $-7.01K
-0.155x 0.00%
2017-12-30 GBX371.60 Million
≈ $45.21K
GBX-57.60 Million
≈ $-7.01K
-0.155x +14.54%
2016-12-31 GBX312.60 Million
≈ $38.03K
GBX-56.70 Million
≈ $-6.90K
-0.181x 0.00%
2016-12-30 GBX312.60 Million
≈ $38.03K
GBX-56.70 Million
≈ $-6.90K
-0.181x -43.32%
2015-12-31 GBX440.90 Million
≈ $53.64K
GBX-55.80 Million
≈ $-6.79K
-0.127x 0.00%
2015-12-30 GBX440.90 Million
≈ $53.64K
GBX-55.80 Million
≈ $-6.79K
-0.127x +34.56%
2014-12-31 GBX190.80 Million
≈ $23.21K
GBX-36.90 Million
≈ $-4.49K
-0.193x 0.00%
2014-12-30 GBX190.80 Million
≈ $23.21K
GBX-36.90 Million
≈ $-4.49K
-0.193x +67.50%
2013-12-31 GBX30.05 Million
≈ $3.66K
GBX-17.88 Million
≈ $-2.18K
-0.595x 0.00%
2013-12-30 GBX30.05 Million
≈ $3.66K
GBX-17.88 Million
≈ $-2.18K
-0.595x --

About NIOX Group PLC

LSE:NIOX UK Medical Devices
Market Cap
$2.95 Million
GBX24.24 Billion GBX
Market Cap Rank
#29490 Global
#589 in UK
Share Price
GBX57.60
Change (1 day)
+2.13%
52-Week Range
GBX54.40 - GBX76.00
All Time High
GBX306.79
About

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide … Read more